Highest-materiality recent filing
Top-line PK results from three-way crossover study expected after May 1, 2026; Periods 2 and 3 scheduled for April 10 and 24.
Inhibitor Therapeutics sues investor for failing to close $3M financing
Filed suit March 30, 2026 against an institutional investor for breach of the Securities Purchase Agreement.
Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants
Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.
Inhibitor Therapeutics enters Frameshift consulting pact for Gorlin syndrome; 18M warrants possible
Entered Master Services Agreement with Frameshift Management for biostatistics, regulatory, and business development support for itraconazole program in Gorlin's syndrome.
Inhibitor Therapeutics signs exclusive worldwide license with JHU for itraconazole in three cancers
Exclusive worldwide license to U.S. Patent 8,980,930 covering itraconazole as an angiogenesis inhibitor.
Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board
Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.
Inhibitor Therapeutics expands board to 7, appoints Ronald Osman; bylaws amended
Board increased from 4 to 7 members; Ronald E. Osman appointed as non-independent director.
Director Michelle Yanez resigns; Michael Jerman appointed to Inhibitor Therapeutics Board
Michelle Yanez resigned from the Board effective May 24, 2023, to take a full-time CFO role elsewhere; no disagreement with the company.
Inhibitor Therapeutics settles derivative and class actions, appoints new CEO and board
Settlement provides $14.25M cash payment to company from Mayne Pharma's D&O insurance.
Mayne to pay $14.25M cash and surrender all its equity (205M+ common shares, convertible preferred, warrants); Mayne debt of $3M canceled.
Director Debra Peattie retires from Inhibitor Therapeutics Board
Debra Peattie retired from Board effective June 1, 2022, to focus on other professional opportunities.
Inhibitor Therapeutics amends loan with Mayne Pharma: limit to $281K, maturity Dec 2022
Facility limit increased by $50,000 to $281,000; maturity extended to December 31, 2022.
On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.
On August 23, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) increased the number of directors on the Board from four (4) members to seven (7) members and appointed Ronald E. Osman to fill one of the vacancies of the Board.
On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an independent member of its Board.
On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”).
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.
On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, Nicholas J. Virca and Garrison J. Hasara (collectively, the “Resigning Officers”) gave notice of the Company of their resignation from their officer positions to be effective on December 13, 2022.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
On December 13, 2022, the Board of the Company appointed Francis E. O’Donnell, Jr., M.D. as Executive Chairman of its Board and as Chief Executive Officer of the Company.
On December 10, 2022, and in furtherance of the transactions contemplated by the Settlement Agreement, W. Mark Watson, Stefan J. Cross, Dr. R. Dana Ono, and Robert D. Martin (collectively, the “Resigning Directors”) gave notice of the Company of their resignation from the Board to be effective on December 13, 2022.
Max materiality 0.90 · Median 0.55 · Most common event other_material